COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | N210455 | JANSSEN PRODUCTS LP
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2023-05-09 | Terminated 2025-02-18 | — | |
Gilead Sciences, Inc. et al v. Apotex Inc. et al 5 patentsANDA 217728darunavir, cobicistat, emtricitabine, and tenofovir alafenamide | D. Del. | 2022-10-25 | Terminated 2025-02-18 | — |
Gilead Sciences, Inc. v. Apotex Inc. et al 2 patentsANDA 217728Tenofovir alafenamide (TAF) | D. Del. | 2022-10-25 | Terminated 2023-08-21 | — |
Gilead Sciences, Inc. et al v. Lupin Limited et al 4 patentsANDA 216511darunavir, cobicistat, emtricitabine, and tenofovir alafenamide (four-drug combination) | D. Del. | 2021-11-16 | Terminated 2025-02-18 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$152.85
per ea
Lowest NADAC/Unit
$152.85
per ea
Brand NDCs
1
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 59676080030SYMTUZA 800-150-200-10 MG TAB | $152.85 | EA | Brand | — | 2026-10-21 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 7700645 | Dec 26, 2026 | — | Yes | Yes | — | — |
| 8148374 | Sep 3, 2029 | — | Yes | Yes | — | |
| 8148374 | Sep 3, 2029 | — | Yes | Yes | — | |
| 8148374 | Sep 3, 2029 | — | Yes | Yes | — | |
| 8148374 | Sep 3, 2029 | — | Yes | Yes | — | |
| 8148374 | Sep 3, 2029 | — | Yes | Yes | — | |
| 8148374 | Sep 3, 2029 | — | Yes | Yes | — | |
| 8754065 | Aug 15, 2032 | — | Yes | Yes | — | |
| 8754065 | Aug 15, 2032 | — | Yes | Yes | — | |
| 9296769 | Aug 15, 2032 | — | Yes | Yes | — | |
| 9296769 | Aug 15, 2032 | — | Yes | Yes | — | |
| 10039718 | Oct 6, 2032 | — | — | Yes | — | — |
| 10786518 | Jul 19, 2038 | — | — | — | — |